Become a member to watch the full episode, plus gain immediate access to our entire back catalog of AMA episodes! Subscribe now: https://bit.ly/3Hfq0kV'>https://bit.ly/3Hfq0kV

In this “Ask Me Anything” (AMA) episode, Peter and Bob discuss all things related to GLP1 agonists—a class of drugs that are gaining popularity for the treatment of obesity. They cover the discovery of these peptides, their physiology, and what it is they do in their natural state. Next, Peter and Bob break down a recently published study which showed remarkable results for weight loss and other metabolic parameters using a onceweekly injection of the GLP1 agonist drug semaglutide, also known as Ozempic, in overweight and obese patients. Finally, they compare results from the semaglutide study to results from various lifestyle interventions and give their take on the potential future of GLP1 agonists.

In this sneak peek, we discuss:
00:00 Intro
00:10 Remarkable results of a recent study in overweight adults
02:15 Key background on insulin, glucagon and the incretin effect to appreciate the effects of semaglutide

In the full episode, we also discuss:
What is GLP1 and how does it work?
2021 semaglutide study: remarkable results, side effects, and open questions;
Semaglutide vs. lifestyle interventions: comparing results with semaglutide vs. lifestyle interventions alone;
Closing thoughts and open questions on the therapeutic potential of semaglutide; and
More.

Read the show notes for this episode here: https://bit.ly/3nbZYac


About:

The Peter Attia Drive is a weekly, ultradeepdive podcast focusing on maximizing health, longevity, critical thinking…and a few other things. With over 35 million episodes downloaded, it features topics including fasting, ketosis, Alzheimer’s disease, cancer, mental health, and much more.

Peter is a physician focusing on the applied science of longevity. His practice deals extensively with nutritional interventions, exercise physiology, sleep physiology, emotional and mental health, and pharmacology to increase lifespan (delay the onset of chronic disease), while simultaneously improving healthspan (quality of life).

Learn more: https://bit.ly/3kBNdUG
Subscribe to receive exclusive subscriberonly content: https://bit.ly/3Hfq0kV'>https://bit.ly/3Hfq0kV
Sign up to receive Peter's email newsletter: https://bit.ly/30mqvII

Connect with Peter on:
Facebook: http://bit.ly/PeterAttiaMDFB
Twitter: http://bit.ly/PeterAttiaMDTW
Instagram: http://bit.ly/PeterAttiaMDIG

Subscribe to The Drive:
Apple Podcast: http://bit.ly/TheDriveApplePodcasts
Overcast: http://bit.ly/TheDriveOvercast
Spotify: http://bit.ly/TheDriveSpotify
Google Podcasts: http://bit.ly/TheDriveGoogle